• Center for Biosimilars
AJMC
AJMC
Stakeholders
Topics
Institute for Value-Based Medicine
About AJMC
News
Media
Conferences
Journals
Compendia
Events
Resources
Subscribe
  • About Us
  • Advertise
  • Contact
  • Do Not Sell My Information
  • Terms & Conditions
  • Privacy Policy

© 2021 MJH Life Sciences and AJMC. All rights reserved.

Stakeholders
  • Academia
  • Employers
  • Health System
  • Payers
  • Providers
Topics
  • Clinical
  • Healthcare Cost
  • Healthcare Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care
Institute for Value-Based Medicine
  • All Coverage
  • Event Coverage
  • Interviews
  • News
About AJMC
  • AJMC Journals
  • Anniversary
  • Author Forms
  • Authors
  • Nominate a Rising Leader
  • About Us
  • Advertise
  • Contact
  • Do Not Sell My Information
  • Terms & Conditions
  • Privacy Policy
  • MJHLS Brand Logo

© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.

Expanding Treatment Options for Metastatic Breast Cancer

  1. home

EP 1: Treatment After Progression on CDK 4/6i in mBC

EP 2: SOLAR-1 Trial in Metastatic Breast Cancer

EP 3: Payer Perspective of Coverage on Cancer Therapies

EP 4: Payer Coverage on Repeat Biopsy in mBC

EP 5: Advantages of Oral Taxanes in mBC

EP 6: Compliance and Adherence to Therapy in mBC

EP 7: Payer Coverage of IV Versus Oral Therapy in mBC

EP 8: Evolving Treatment Landscape of R/R HER2+ mBC

EP 9: HER2CLIMB and NALA Trials: R/R HER2+ mBC

EP 10: SOPHIA Trial in R/R HER2+ mBC

EP 11: Sequencing of Therapy in R/R HER2+ mBC

EP 12: IMpassion130 Trial Data on PD-L1+ Tumors in TNBC

EP 13: Role of PARP Inhibition and I/O Therapy in TNBC

EP 14: Treatment Options in Metastatic TNBC

EP 15: Considerations for NGS Testing in mTNBC

EP 16: Assessing the Value of Personalized Treatment in mBC

EP 17: Closing Thoughts on Metastatic Breast Cancers